article thumbnail

STAT Virtual Event | Tomorrow’s Trailblazers in Science

STAT

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Each year, STAT chooses a new class of Wunderkinds, showcasing stars of science and medicine who are in the midst of launching their careers.

273
273
article thumbnail

STAT Virtual Event | Cancer’s Breakthrough Engine

STAT

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Since the development of Gleevec two decades ago, precision cancer medicines have become a driving force in biotech and a source of hope for cancer patients. Read the rest…

289
289
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Virtual Event: March of the Biosimilars

STAT

Editor’s note: A livestream of this event will be embedded below at 1 p.m. Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines?

article thumbnail

STAT Virtual Event | 2024 JPM Recap, Live!

STAT

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Relive this year’s J.P. Morgan Healthcare Conference with the STAT reporters who attended. Get a full rundown of the deals, data, and scuttlebutt and come away with the ideas and water-cooler chatter you need for the year ahead.

296
296
article thumbnail

STAT Virtual Event | Navigating a New Era in Alzheimer’s Treatment

STAT

Editor’s note: A livestream of the event will be embedded below at 1 p.m. It took decades for scientists to come up with treatments that could slow the progression of Alzheimer’s disease. Now patients and physicians face a new challenge: actually getting the medicines to people who might benefit from them.

199
199
article thumbnail

STAT Virtual Event: Putting AI to the Test

STAT

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Enough talk about fairness, safety, and effectiveness. If we want AI systems to possess these attributes in health care, we have to test them with those goals in mind. Read the rest…

283
283
article thumbnail

STAT+: The biotech scoreboard for the second quarter: 32 stock-moving events to watch

STAT

Here is STAT’s biotech scoreboard, our regular ledger of stock-moving biotech events, for the second quarter and middle of the year: Obesity catalysts, first. Danish drugmaker Zealand Pharma — yes, there’s another Danish drug maker in obesity — is developing a long-acting amylin analog called petrelintide.

280
280